2013-韩国随机对照研究-2年联合治疗后，停用5aRI和AB后的对比.pdfVIP

Prostatic Diseases and Male Voiding Dysfunction Progression of Lower Urinary Tract Symptoms After Discontinuation of 1 Medication From 2-Year Combined Alpha-blocker and 5-Alphaereductase Inhibitor Therapy for Benign Prostatic Hyperplasia in Men e A Randomized Multicenter Study Victor Chia-Hsiang Lin, Chun-Hou Liao, and Hann-Chorng Kuo OBJECTIVE To investigate the treatment outcome of discontinuing 1 medication from 2-year combination therapy for male benign prostatic hyperplasia/lower urinary tract symptoms. MATERIALS AND Patients with International Prostate Symptom Score 8, total prostatic volume (TPV) 30 mL, METHODS and maximum flow rate (Qmax) 15 mL/s were randomly assigned to the 5a-reductase inhibitor (5ARI) discontinue (DC-5ARI) or a-blocker discontinue (DC-a-blocker) group. All patients received combination therapy with dutasteride (5 mg QD) and doxazosin (4 mg QD) for 2 years and then discontinued either one drug for 12 months. The primary endpoint was the occurrence of resuming medication. The secondary endpoints were the net parameters changed or the need of transurethral resection of the prostate (TURP). RESULTS A total of 117 patients in DC-5ARI and 113 in DC-a-blocker group completed the study. The baseline TPV and Qmax were similar between groups before combination therapy. Resumption of combination therapy was significantly more in DC-5ARI than DC-a-blocker group (51.3% vs 31.0%; P ¼ .005). The mean duration from discontinuing to resuming medication was 5.0 4.4 months in DC-a-blocker and